<?xml version="1.0" encoding="UTF-8"?>
<BillSummaries>
<item congress="113" measure-type="s" measure-number="2012" measure-id="id113s2012" originChamber="SENATE" orig-publish-date="2014-02-11" update-date="2014-09-15">
<title>Designer Anabolic Steroid Control Act of 2014</title>
<summary summary-id="id113s2012v00" currentChamber="SENATE" update-date="2014-09-15">
<action-date>2014-02-11</action-date>
<action-desc>Introduced in Senate</action-desc>
<summary-text><![CDATA[<p>Designer Anabolic Steroid Control Act of 2014 - Amends the Controlled Substances Act to:&nbsp; (1) expand the list of substances defined as "anabolic steroids&quot;;&nbsp;(2) authorize the Attorney General to issue a temporary order adding a drug or other substance to the list of anabolic steroids;&nbsp;(3) impose enhanced criminal and civil penalties for&nbsp;possessing or trafficking in any anabolic steroid, or product containing an anabolic steroid, unless it bears a label clearly identifying the anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry;&nbsp;and (4) authorize the Attorney General to collect data and analyze products to determine&nbsp;whether they contain anabolic steroids and are properly labeled.</p> <p>Specifies that a substance shall not be considered to be a drug or hormonal substance that is considered to be an anaboloic steroid if it is: (1) an herb or other botanical; (2) a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; (3) a combination of two or more such substances (i.e., botanical or concentrate, metabolite, or extract); or (4) a dietary ingredient for purposes of the Federal Food, Drug, and Cosmetic Act. Provides that any person claiming the benefit of an exemption or exception from being considered a drug or hormonal substance shall bear the burden of providing the appropriate evidence.</p> <p>Directs: (1) the United States Sentencing Commission to review and amend federal sentencing guidelines with respect to offenses involving anabolic steroids, and (2) the Administrator of the Drug Enforcement Administration (DEA) to report every two years on what anabolic steroids have been scheduled on a temporary basis under this Act.</p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
